Asia  Health Care Blog
Exploring the Intersection of Business, Policy and Culture, in the Asian Health Care Space


Business & Investment

April 16, 2012

No Quick Fix

More articles by »
Written by: Benjamin
Tags: , , ,
China-Earthquake-Victims-42106

Over at today’s Asia Times, I have a column up on China’s healthcare reforms.  In it, I argue that not since Deng smashed the “iron rice bowl” has the country faced as difficult, nor as sensitive, a set of reforms.  Unlike Deng’s reforms, the country now enjoys a certain wealth while access to healthcare has actually decreased.  Consequently, the country’s healthcare reforms carry with them cultural and political stakes much higher than many outsiders appreciate.  At the same time, the indispensable role of private enterprise – whether pharma, medical device, or hospital entrepreneurs and investors – is coming under question as policies like those of the Anhui pricing model are elevated.

A segment of the column follows:

Rural Chinese have long known that money buys better outcomes; what is happening more broadly within Chinese society is that an awareness of the potential for better outcomes is outpacing access to these enabling technologies. Because of this, the third dimension of healthcare reform must deal with the realization that as Chinese are shown the potential life-saving possibilities of modern medicine, many will find them out of reach financially.

Consequently, it will be difficult to prevent a certain cynicism from growing about the role of additional market reforms, let alone the primacy Western governments want Beijing to place on the role of the free market in solving China’s healthcare problems. In this way, successful healthcare reform is likely to color the country’s attitudes towards future economic reforms at both a popular and policy levels.

The full article can be read here.



About the Author

Benjamin
Ben is the Founder and Managing Director of Rubicon Strategy Group, a consulting firm specializing in helping American and European companies enter emerging markets. He is a member of the National Committee on US-China Relations and holds an advisory board seat at Indiana University’s Research Center on Chinese Politics and Business. He is a columnist for the Asia Times on US-China trade and economic policy matters, with a particular focus on how relations between the two countries are being impacted post the 2008 financial crisis. As a founder of the consulting firm Teleos, he was an early advocate for Chinese companies moving away from cost-only business models towards ones that emphasized brand building, innovation and product development. He founded Teleos Healthcare which licensed, capitalized and commercialized the IP for an OTC medical appliance used to help stop nosebleeds. This company successfully partnered with a major US pharmaceutical company on the product launch for the hemophilia and VWD bleeding disorder community. In addition, Ben has successfully managed projects in China across a number of industries, ranging from consumer goods to more complex engineered products. He holds his MBA from Duke University in Durham, North Carolina.




0 Comments


Be the first to comment!


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>